Back to Search
Start Over
Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series.
- Source :
- Acta Dermato-Venereologica; Jan2020, Vol. 100 Issue 1, p1-2, 2p
- Publication Year :
- 2020
-
Abstract
- The article discusses the Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis. It mentions Dupilumab (DUPI) is an anti-interleukin-4-receptor-α monoclonal antibody that blocks signalling of interleukin 4 and interleukin 13, which are involved in numerous allergic diseases ranging from asthma to atopic dermatitis.
- Subjects :
- ATOPIC dermatitis
TEENAGERS
Subjects
Details
- Language :
- English
- ISSN :
- 00015555
- Volume :
- 100
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Acta Dermato-Venereologica
- Publication Type :
- Academic Journal
- Accession number :
- 141300961
- Full Text :
- https://doi.org/10.2340/00015555-3368